Dr. Belldegrun joined Cougar Biotechnology, Inc. in December 2003 as Vice Chairman of the Board of Directors and Chairman of the Scientific Advisory Board. Dr. Belldegrun is Chief of the Division of Urologic Oncology and holds the Roy and Carol Doumani Chair in Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).
He is also the Founder of Agensys, Inc., a privately held biotechnology company focused on the development of fully human monoclonal antibodies to treat solid tumor cancers based on Agensys' proprietary targets. Dr. Belldegrun served as founding Chairman of Agensys from 1997-2002 and currently serves on Agensys' Board of Directors and as a consultant.
He completed his medical degree at the Hebrew University Hadassah Medical School in Jerusalem, his post graduate fellowship at the Weizmann Institute of Science and his residency in Urology at Harvard Medical School. Prior to UCLA, Dr. Belldegrun was at the National Cancer Institute/NIH as a research fellow in surgical oncology under Steven A. Rosenberg, MD, PhD. He is certified by the American Board of Urology and a Fellow of the American College of Surgeons.
Dr Belldegrun is also on the scientific boards of several biotechnology and pharmaceutical companies and serves as a reviewer for many medical journals and granting organizations including the Journal of Urology and the American Foundation of Urologic Diseases. In addition to holding several patents, Dr. Belldegrun is the author of several books on prostate and kidney cancers and has written over 250 scientific publications with an emphasis on urologic oncology, particularly kidney, prostate and bladder cancers.
Lindsay A. Rosenwald, MD
Chairman, Founder
Paramount Capital, Inc.
Dr. Rosenwald is the Chairman and Chief Executive of the Paramount Capital group of companies. The Paramount Capital group of companies specializes in asset management, investment banking, venture capital and direct investing within the biotechnology and life-sciences industry. Paramount Capital Asset Management, Inc. manages investor assets through domestic and offshore hedge funds, as well as private equity. Paramount Capital Inc., a NASD member broker dealer, specializes in conducting private placement offerings for public and private development stage biotechnology companies. Paramount Capital Investments, LLC is a venture capital organization that takes a controlling interest in public and private companies, including start-ups and distressed turn-around companies.
Dr. Rosenwald has been a Wall Street biotechnology entrepreneur for over 17 years and has been instrumental in the founding and re-capitalization of dozens of public and private biotechnology and life-sciences companies. Paramount's portfolio companies have already seen three new chemical entities approved by the FDA and currently have dozens of compounds in clinical trials. One portfolio company, PolaRx BioPharmaceuticals, Inc., received final marketing approval for its cancer drug, Arsenic Trioxide, only 30 months after the first patient was treated in a corporate clinical trial, a record in the industry. In addition to Cougar Biotechnology, Dr. Rosenwald has financed or founded Cypress Bioscience, Inc., Bradley Pharmaceuticals, Inc., Genta, Inc, Repligen Corporation, Discovery Laboratories, Inc., Avigen, Inc., Indevus Pharmaceuticals, Inc., Cardiome Pharma Corp., Keryx Biopharmaceuticals, Inc., Neose Technologies Inc., Cell Therapeutics, Inc., Biocryst Pharmaceuticals, Inc and Hudson Health Sciences, Inc.
Dr. Rosenwald received his M.D. from Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.
Russell H. Ellison, MD, MSc
Vice President of Clinical Development
Fibrogen, Inc.
Dr. Ellison is currently the Vice President of Clinical Development of Fibrogen, Inc, a privately held biotechnology-based drug discovery company using its expertise in the fields of tissue fibrosis, connective tissue growth factor (CTGF), and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for fibrotic disorders, diabetic complications, anemia, ischemic disease, cancer, and other areas of unmet medical need.
Prior to Fibrogen, Dr. Ellison was the Vice President of Medical Affairs, and Chief Medical Officer of Sanofi-Synthelabo, where he was responsible for several key oncology products including Eloxatin (oxaliplatin) for colorectal cancer and Eligard (leuprolide acetate for injectable suspension) for prostate cancer. Dr. Ellison also served as Vice President, Medical Affairs and Chief Medical Officer of Hoffmann La Roche, Inc. from 1997 through 2002 and held several drug development positions with Roche Canada from 1990 to 1997. Dr. Ellison holds an M.D from the University of British Columbia and an MSc (with distinction) from The London School of Tropical Medicine and Hygiene.
Carl S. Goldfischer, M.D.
Director
Carl S. Goldfischer, M.D., has been a director since 2000. He is a Managing Director of Bay City Capital and serves on its Board of Directors and Executive Committee. Dr. Goldfischer's background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously, Dr. Goldfischer was a Research Analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer currently serves as Chairman of the Board of Syntonix Pharmaceuticals, and as a director for Avera Pharmaceuticals, BrainCells, Inc., EnteroMedics, Etex Corporation, MAP Pharmaceuticals, Metabolex, and PTC Therapeutics. Dr. Goldfischer is also a member of the Board of Trustees of Sarah Lawrence College. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College.
David T. Hung, M.D.
President and Chief Executive Officer, Director
Dr. Hung became president and chief executive officer of Medivation, Inc. and a member of the Board of Directors when the Company acquired its subsidiary Medivation Neurology, Inc. in December 2004. He served as president, chief executive officer and director of Medivation Neurology, Inc. since its inception in September 2003. From 1998 to 2001, Dr. Hung served as chief scientific officer (1998-1999) and as president, chief executive officer and director (1999-2001) of ProDuct Health, Inc., a privately-held medical device company. ProDuct Health, Inc. took its first product (a breast cancer cytological diagnostic product) from a prototype design through a 507 patient clinical trial and through FDA marketing clearance in 16 months. It was acquired in 2001 by Cytyc Corporation for $167 million after having spent only approximately $22 million in total development costs. From 1994 to 1998, Dr. Hung served in various senior positions at Chiron Corporation, most recently as vice president of lead discovery and development and vice president of new projects. Dr. Hung received an M.D. Alpha Omega Alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in biology from Harvard College
Lynn Seely, M.D.
Chief Medical Officer
Dr. Seely joined Medivation as chief medical officer in May 2005. From 2002 to 2005, she served as vice president of clinical development at Corgentech, Inc., a biomedical company. She served as vice president of clinical development at ProDuct Health, Inc., a privately-held medical device company, from 2000 to 2001, and subsequently served as vice president of clinical development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, from 2001 to 2002. While there she assisted with transitional matters related to Cytyc Corporation's acquisition of ProDuct Health, Inc. From 1996 through 2000, she served as an associate director of clinical development at Chiron Corporation. Dr. Seely has led teams running clinical trials in all phases of development in a variety of therapeutic indications. Dr. Seely received an M.D. Alpha Omega Alpha from the University of Oklahoma, College of Medicine and completed her residency and served as chief resident in internal medicine at Yale-New Haven Hospital. She is board-certified in internal medicine and endocrinology and metabolism and was on faculty at the University of California, San Diego prior to joining industry.
Antonio J. Grillo-López, M.D.
Chairman, Neoplastic and Autoimmune Diseases Research Institute/Chief Medical Officer Emeritus, IDEC Pharmaceuticals Corporation
Antonio J. Grillo-López, M.D. has served as a Director since September 2002. From November 1992 to January 2001, Dr. Grillo-López served as Chief Medical Officer of IDEC Pharmaceuticals Corporation and from January 2001 to November 2003 held the position of Chief Medical Officer Emeritus of IDEC Pharmaceuticals Corporation. Dr. Grillo-López serves on the boards of directors of Favrille, Inc. and Salmedix, Inc., and on the scientific advisory boards of Favrille, Inc., Conforma Therapeutics Corporation, SuperGen, Inc., Salmedix, Inc., Seattle Genetics, Inc., Attenuon LLC and Nereus Pharmaceuticals. Dr. Grillo-López holds a B.S. and an M.D. from the University of Puerto Rico.
Neil James Clendeninn, Ph.D, MD
Dr. Clendeninn served as Corporate Vice President, Head of Clinical Affairs of Agouron Pharmaceuticals, Inc., a subsidiary of Pfizer Inc., from 1993 until his retirement in 2001. With Agouron, Dr. Clendeninn was responsible for development and growth of the Clinical Development Department from pre-clinical phase to phase IV, rapid delivery to market for Viracept, an HIV Protease Inhibitor. Under his leadership, the department grew to over 200 MDs, Ph.Ds and clinical pharmacologists, biostatisticans, data management group and a post marketing medical team. Previous to Agouron, Dr. Clendeninn served as Director of the Clinical Oncology Department for Burroughs Wellcome Company. His other past positions include assistant clinical professor in oncology at the University of North Carolina, senior staff member at the National Cancer Institute, and other general practice and academic-based positions. Dr. Clendeninn has led extensive research in areas that include chemotherapeutic multi-drug resistance, opiate receptors and photochemistry. He has written and co-authored numerous publications including, "The Approach to the Pre-clinical and Clinical Development of a Selective Matrix Metalloprotease Inhibitor (MMP); Prinomastat (AG3340)", July 2000. Dr. Clendeninn currently serves on the boards of Oncogenex Technologies Inc. and on the Board of Scientific Advisors for the National Cancer Institute. Dr. Clendeninn holds a BA Biology/Chemistry from Wesleyan University, CT, and a Ph.D Microbiology/Pharmacology and MD from New York University, NY.
N. ANTHONY COLES, M.D., M.P.H.
President and Chief Executive Officer
Dr. Coles joined NPS Pharmaceuticals in November 2005 as president, chief operating officer, and a member of the Board of Directors. In May 2006 he was appointed chief executive officer. Dr. Coles joined NPS from Vertex Pharmaceuticals where, from 2002 to October 2005, he was senior vice president, commercial operations and pharmaceutical products. From 1996 to 2002 Dr. Coles held a variety of positions with Bristol-Myers Squibb including senior vice president of strategy and policy; senior vice president, marketing and medical affairs for the neuroscience, infectious disease and dermatology division; vice president, west area sales cardiovascular and metabolic business unit for U.S. Primary Care; and vice president, cardiovascular global marketing. Prior to joining BMS, Dr. Coles was vice president of the Hypertension and Heart Failure Business Group at Merck. Dr. Coles holds an M.D. from Duke University, a master's degree in public health from Harvard University, and a B.S. from Johns Hopkins University.
CALVIN R. STILLER, M.D.
Chairman and Chief Executive Officer, Stilco Investments Limited
Dr. Stiller has served as a director since the closing of our acquisition of Allelix Biopharmaceuticals, Inc. in December 1999; he had served on the board of Allelix since April 1999. Dr. Stiller is chairman of the board and chief executive officer of Stilco Corporation and BioQuest Innovations Inc. From 1996 to 2005, Dr. Stiller served as chairman and chief executive officer of Canadian Medical Discoveries Fund. Dr. Stiller served as the chief of the Multi-Organ Transplant Service at the University Hospital in London, Ontario from 1984 through 1996. He is professor emeritus of medicine at the University of Western Ontario. Dr. Stiller was the chairman of the Ontario Research and Development Challenge Fund and is a cofounder and director of MaRS Discovery District, and the Ontario Institute for Cancer Research. He serves as a director of Residential Retirements REIT and Vasogen Corporation. Dr. Stiller received an M.D. degree from the University of Saskatchewan.
Eugene A. Bauer, M.D.
Eugene A. Bauer, M.D. has served on the Company's Board of Directors since February 2005. Dr. Bauer brings corporate, industry and academic experience to Protalex. Dr. Bauer is currently Chief Executive Officer and a board member of Neosil Inc., a privately held biotechnology company. Prior, Dr. Bauer was a Senior Client Partner with Korn/ Ferry International and was a founder of Connetics Corporation, a specialty pharmaceutical company, where he continues to serve as an Emeritus Director. Dr. Bauer was previously affiliated with Stanford University Medical Center, serving as Vice President of the center from 1997 to 2001; Dean of the Stanford University School of Medicine from 1995 through 2001; a. Professor in the department of dermatology since 1988; and was Chief of the Dermatology Service at Stanford University Hospital from 1988 to 1995. For the preceding six years, Dr. Bauer was a professor at Washington University School of Medicine. During his career, Dr. Bauer has served as Chairman of two National Institutes of Health study sections of the National Institute of Arthritis and Musculoskeletal and Skin Diseases and has served on a board of scientific counselors for the National Cancer Institute. Dr. Bauer also serves as a director of both Peplin LTD, an Australian public corporation, and of Echo Healthcare Acquisition Corp, a publicly held SPAC and a non-profit Dermatological Organization. Dr. Bauer holds B.S. and M.D. degrees from Northwestern University.
Mitchell H Gold MD
CEO/President/Director at
Dendreon Corporation
Seattle, Washington
HEALTHCARE / BIOTECHNOLOGY
Officer since April 2000
Director since May 2002
Track This Person
40 years old
Mitchell H. Gold, M.D., age 40, has served as our Chief Executive Officer since January 1, 2003, and as a director since May 2002. Dr. Gold also served as the Company's Vice President of Business Development from June 2001 to May 2002, and as the Company's Chief Business Officer from May 2002 through December 2002. From April 2000 to May 2001, Dr. Gold served as Vice President of Business Development and Vice President of Sales and Marketing for Data Critical Corporation, a company engaged in wireless transmission of critical healthcare data, now a division of GE Medical. From 1995 to April 2000, Dr. Gold was the President and Chief Executive Officer, and a co-founder of Elixis Corporation, a medical information systems company. From 1993 to 1998, Dr. Gold was a resident physician in the Department of Urology at the University of Washington. Dr. Gold currently serves on the boards of the University of Washington/Fred Hutchinson Cancer Research Center Prostate Cancer Institute and the Washington Biotechnology and BioMedical Association. Dr. Gold received his B.S. from the University of Wisconsin-Madison and his M.D. from Rush Medical College.
Prior to co-founding De Novo, Dr. Mauney was a Partner at Asset Management Company, where he worked with Pitch Johnson as the lead partner in healthcare investments. At AMC, he led seed and early stage investments in TriVascular (acquired by Boston Scientific), Novare Surgical Systems (licensed to Johnson & Johnson), Enteric Medical Technologies (acquired by Boston Scientific), and participated in seven financings of technology companies. Dr. Mauney was the first employee and Director of Business Development for Fox Hollow Technologies (Nasdaq: FOXH) and worked in product management for Heartport (acquired by Johnson & Johnson).
He earned his MD degree from The Dartmouth School of Medicine and a BA from Duke University.
Gil Kliman, M.D., focuses on life sciences investing with a special interest in medical devices. He is responsible for a broad portfolio of life sciences companies, including Archus Orthopedics, Epocrates, Glaukos, Neuropace, Ophthonix, and ReVision Optics. He was one of the early lead investors in IntraLase, an ophthalmic laser company which went public in 2004 and was acquired by Advanced Medical Optics (NYSE: EYE) for $808MM in 2007.
Prior to InterWest Partners, Dr. Kliman was a healthcare investor at TA Associates and at Norwest Venture Capital. As a practicing ophthalmologist he was the former west coast director of LCA Vision, and served as an assistant professor at Tufts New England Eye Center.
Dr. Kliman received his B.A. from Harvard University, M.D. from the University of Pennsylvania and M.B.A. from Stanford University.
Representative Previous Investments:
IntraLase - acquired by Advanced Medical
Optics (EYE)
Spinal Dynamics - acquired by Medtronic (MDT)
A Word from Gil
"Over the last 20 years I have had the privilege of diverse life experiences as a practicing physician, start-up company founder, and technology venture capitalist. I most enjoy being on the front edge of new technology waves, looking over the horizon for non-obvious opportunities... What I find exciting is working alongside visionary entrepreneurs, thinking outside the box, and helping to identify creative strategies to make pioneering ventures even more successful."
Robert Garland, MD
Partner
Investing Area: Medical and Life Sciences
Robert joined NEA in December 2003 as a Principal and became a Partner in 2007. He invests in biopharmaceuticals and medical devices. Robert is a director of Cardioxyl Pharmaceuticals. Prior to NEA, in addition to clinical practice, he was with McKinsey & Company's Pharmaceutical & Medical Products and Corporate Finance & Strategy practices. At McKinsey, Robert worked with biotech, pharmaceutical, medical device, diagnostics, and private equity clients to evaluate investments, formulate product and corporate strategies and build businesses. Robert completed his Residency in Internal Medicine and Fellowship in Infectious Diseases at the University of California, San Francisco. He received his MBA and MPH from the University of California, Berkeley, his MD from Baylor College of Medicine, and his BSEE from Rice University.
Josh Makower, MD
Venture Partner
Investing Area: Medical and Life Sciences
Josh joined NEA in September 2004 as a Venture Partner. He works closely with NEA's healthcare team and focuses primarily on medical devices and pharmaceutical investments. Josh is also the Founder & Chief Executive Officer of ExploraMed II and III, Inc., both NEA portfolio companies created to be medical device incubators based on the West Coast. Acclarent, Inc. and NeoTract, Inc. have both been created by ExploraMed II and are launched and independently funded. In addition, Josh serves a part-time role on the faculty of the Stanford University Medical School as a Consulting Associate Professor of Medicine and is Co-Director of Stanford's Biodesign Innovation Program. Josh serves on the Board of Directors for Acclarent, Inc., NeoTract, Inc., ExploraMed II and III and Intrinsic Therapeutics, Inc. Prior to NEA, Josh was Founder, Chairman and Chief Technical Officer of TransVascular, Inc. (acquired by Medtronic, Inc. in 2003), and Founder and Chairman of EndoMatrix, Inc. (acquired by C.R. Bard in 1997.) Up until 1995, Josh was Founder and Manager of Pfizer's Strategic Innovation Group. Josh holds over four dozen patents for various medical devices in the fields of cardiology, ENT, general surgery, drug delivery and urology. He received a Masters of Business Administration from Columbia University, a Doctor of Medicine degree from the New York University School of Medicine, and a Bachelor of Science in Mechanical Engineering from the Massachusetts Institute of Technology.
Justin Klein, MD, JD
Senior Associate
Investing Area: Medical and Life Sciences
Justin joined NEA's healthcare team in 2006 and focuses on medical device, biopharmaceutical, specialty pharmaceutical, and healthcare services company investments. Previously, he worked for the Duke University Health System, reporting directly to the CEO and the COO of Duke University Hospital on health system strategy, finance and clinical service unit operations. In addition, he has worked at Latham & Watkins LLP in Menlo Park, where he assisted life sciences companies on numerous licensing transactions, regulatory and corporate securities matters. Justin currently serves as a member of the Board of Trustees of Duke University, and has previously served on Duke University Medical Center's Institutional Review Board. Justin concurrently earned his MD from the Duke University School of Medicine and his JD from Harvard Law School. He received his AB in Economics and his BS in Biological Anthropology and Anatomy from Duke University.
Dual degree helps Medical School graduates take on business world
He's been called an all-star, the best of the best. When it comes to assessing emerging drugs and biotechnologies, few physicians can top Lindsay Rosenwald. He's definitely the specialist to see if your hedge fund is ailing.
But if your health is at issue, you'll have to go elsewhere, because even though this highly successful venture capitalist has a medical degree, he doesn't practice medicine.
Rosenwald is chairman, CEO and founder of the Paramount Capital group of companies. With offices on three continents, Paramount specializes in asset management, investment banking, venture capital and direct investing in the biotechnology and life-sciences industries.
"I manage investor assets through domestic and offshore hedge funds as well as private equity," Rosenwald said, "and conduct private placement offerings for development-stage biotechs — or take controlling interest in start-ups and turnarounds, both private and public."
For some alumni, the transition from exam room to boardroom followed an unforeseen progression. But not in Rosenwald's case. It was all part of a plan. He majored in finance and economics as an undergraduate.
"While in medical school, I never let my Wall Street Journal subscription lapse," he said.
Rosenwald isn't the only School of Medicine graduate who is a major player in the world of business and finance. Many other Medical School alumni work for big corporations, and others for themselves. Most of their businesses are related to medicine, but others have ventured into nonmedical zones.
Daly
"Once upon a time, people went to medical school because they wanted to practice medicine, conduct research or teach," said John M. Daly, dean of the School of Medicine. "But applicants' motivations run a much wider gamut these days. We don't seek out M.D. degree candidates who intend not to practice medicine, but we absolutely do expect more of our graduates to embark on nontraditional careers — and even ‘traditional' careers aren't what they used to be," he said.
Alexander M. Hamling, who will graduate with the School of Medicine's class of 2006, knows exactly what Daly means. He and the seven other candidates in Temple's five-year dual-degree M.D.-M.B.A. program are doing all they can to prepare for the realities of medicine as a business. Temple's "regular" Medical School curriculum also incorporates more business-related material than it did in the old days.
"No one believes adages like ‘take care of the patients and the bills will take of themselves' anymore," said Hamling, explaining that today's medical students recognize that without a business setting, there is no clinical setting, that it takes more than just good doctoring to run a successful practice.
A decade ago, M.D.-M.B.A. programs didn't even exist. So when the golden age of medicine started tarnishing, there were thousands of alumni out there who had to learn "the hard way." And many learned their lessons well, becoming highly successful in business and in medicine.
Medical practices are businesses — and some contain opportunity for profit no one would have considered in the past. For example, who says you have to send a patient to the hospital for an MRI exam if you can invest in one yourself? Or consider the fact that most of the 4,000 ambulatory surgery centers in the United States are owned by physicians.
Apart from — or instead of — their own practices, some entrepreneurial alumni go into businesses that solve business or clinical problems for other physicians or scientists. Some forge out their own business niches, others form partnerships with investors or corporations seeking new business, and others still seek full- or part-time employment in industries such as pharmaceuticals and medical devices.
In business and industry as well as in medicine, one factor is key: critical thinking. Critical thinking skills will take you far in any direction you choose, said Calvin Johnson, the state secretary of health and clinical associate professor of pediatrics at Temple, during his keynote address at the Medical School's commencement in May.
"The skills and abilities you developed at Temple will serve you well wherever you apply them, wherever you want to go," Johnson said.
